- Closed system transfer devices, designed to minimize the risk of exposure to hazardous drugs, are increasingly vital components of modern healthcare safety protocols, particularly in oncology, pharmacy compounding, and hospital environments. These devices play a crucial role in protecting healthcare workers by preventing the escape of drug vapors and aerosols during preparation and administration
- The escalating demand for closed system transfer devices is primarily fueled by the growing emphasis on occupational safety in healthcare settings, increasing adoption of hazardous drug handling guidelines (such as USP <800> in the U.S.), and rising cancer prevalence globally that is driving the use of cytotoxic medications
- U.S. dominated the North America closed system transfer devices market with the largest revenue share of 82.3% in 2024, owing to early regulatory enforcement through USP <800> compliance measures, high healthcare expenditure, and a strong presence of key market players. The country experienced substantial growth in Closed System Transfer Devices deployment, particularly across hospitals, oncology clinics, and compounding pharmacies, driven by stringent safety mandates and the rising incidence of hazardous drug handling in cancer treatment settings
- Canada is expected to be the fastest growing country in the in North America closed system transfer devices market during the forecast period, supported by rising awareness of healthcare worker safety and the expansion of cancer treatment programs across various provinces. Regulatory efforts from Health Canada and the integration of occupational safety standards in both hospital and homecare settings have significantly driven the adoption of Closed System Transfer Devices in the country
- The Needle-Free Closed System Transfer Devices segment dominated with a 58.7% revenue share in 2024, owing to its widespread adoption in reducing needlestick injuries and contamination risk
